(Total Views: 678)
Posted On: 09/30/2021 9:42:17 PM
Post# of 154138
In the overall population (30 patients) it showed only "slightly increased mPFS" with MOS "similar" to SOC.
In the 73% of patients that were responders is where you see the phenomenal results.
Right now they're trying to figure out why some are responders and some are not. Once they know that they can configure a trial that excludes non-responders if necessary. Since the main trial was a dose escalation trial starting at 350mg and the compassionate use was 350mg (although escalation may have occurred) it could be as simple as a large percentage of non-responders not getting a high enough dose.
In the 73% of patients that were responders is where you see the phenomenal results.
Right now they're trying to figure out why some are responders and some are not. Once they know that they can configure a trial that excludes non-responders if necessary. Since the main trial was a dose escalation trial starting at 350mg and the compassionate use was 350mg (although escalation may have occurred) it could be as simple as a large percentage of non-responders not getting a high enough dose.
(10)
(0)
